Institution
Hofstra University
Education•Hempstead, New York, United States•
About: Hofstra University is a education organization based out in Hempstead, New York, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 6341 authors who have published 11896 publications receiving 268028 citations.
Topics: Population, Medicine, Health care, Poison control, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This clinical review article examines current strategies for identifying patients with opioid use disorder, the treatment of patients with acute opioid withdrawal syndrome, approaches to medication‐assisted therapy, and the transition of patients from the emergency department to outpatient services.
78 citations
••
TL;DR: The data surrounding the development, validation, and clinical and economic utility of the Oncotype DX(®) colon cancer assay is summarized, a multigene expression assay validated to independently predict recurrence risk in patients with stage II and III colon cancer beyond traditional factors.
Abstract: Advances in molecular biology have enabled identification of tumor biomarkers that allow for individualized risk assessment for patients with cancer. Molecular predictors of clinical outcome can help inform discussion regarding the role of adjuvant chemotherapy in patients with resected colon cancer, such as those with stage II colon cancer in which the benefit of adjuvant therapy is controversial or those with stage III colon cancer who may have a lower risk of recurrence and less absolute benefit from oxaliplatin therapy. This article summarizes the data surrounding the development, validation, and clinical and economic utility of the Oncotype DX ® colon cancer assay, a multigene expression assay validated to independently predict recurrence risk in patients with stage II and III colon cancer beyond traditional factors.
78 citations
••
TL;DR: In this paper, the authors investigated the concept of a "Thruport", a facility designed to handle high volume transmodal rail shipments, and argued that the Thruport represents a step in the evolution of intermodal transportation and containerization for inland transport systems.
78 citations
••
TL;DR: Additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.
Abstract: Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, especially cardiometabolic dysregulation. This review evaluates new/emerging pharmacological treatments for schizophrenia. Therapies targeting total symptoms include cannabidiol, D3 antagonist/5-HT1A partial agonist F17464, lumateperone (ITI-007), phosphodiesterase 10A (PDE10A) inhibitors MK-8189 and TAK-063, sodium nitroprusside, and trace amine-associated receptor-1 (TAAR1) agonist RO5263397 and SEP-363856. Treatments targeting negative symptoms include the PDE10A inhibitor LuAF-11167, 5-HT2A inverse agonist pimavanserin, sigma-2/5-HT2A antagonist roluperidone (MIN-101), and d-amino acid oxidase (DAAO) inhibitor TAK-831. Agents targeting primarily cognitive dysfunction are the glycine transporter-1 inhibitor BI-425809 and cannabidiol. Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D1/D2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Two new long-acting injectable antipsychotic formulations, Aripiprazole Lauroxil NanoCrystal® and the first subcutaneous injectable LAI Perseris (RBP-7000), were recently approved by U.S. Food and Drug Administration, and positive results were announced for Risperidone ISM®, each achieving therapeutic levels within 24 hours, without need for initial oral cotreatment/loading injection-strategies. Paliperidone palmitate 6-monthly intramuscularly injectable and Risperidone subcutaneously injectable TV46000 are currently under investigation. Finally, the samidorphan+olanzapine combination targets reduced weight gain liability, while maintaining olanzapine's efficacy. Most of these trial programs are still ongoing or have yielded mixed or even negative results. Thus, additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.
78 citations
••
Charité1, Indiana University2, University of São Paulo3, Tufts University4, University of Glasgow5, Vanderbilt University6, Baylor University Medical Center7, Stanford University8, Memorial University of Newfoundland9, Hofstra University10, Emory University11, Johns Hopkins University12, University of Texas Health Science Center at San Antonio13, Baylor College of Medicine14
TL;DR: Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of compounds that stimulate endogenous erythropoietin production as discussed by the authors.
Abstract: Background Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of compounds that stimulate endogenous erythropoietin production. Methods We conducted two r...
78 citations
Authors
Showing all 6443 results
Name | H-index | Papers | Citations |
---|---|---|---|
Kevin J. Tracey | 138 | 561 | 82791 |
David B. Allison | 129 | 836 | 69697 |
John M. Kane | 125 | 752 | 60886 |
Peter K. Gregersen | 124 | 451 | 60278 |
Daniel E. Singer | 123 | 445 | 64998 |
Kenneth L. Davis | 113 | 622 | 61120 |
Michael L. Blute | 112 | 527 | 45296 |
David B. Tanner | 110 | 611 | 72025 |
Bertram Pitt | 107 | 754 | 78458 |
John D. Reveille | 102 | 519 | 38105 |
Christoph U. Correll | 100 | 755 | 37523 |
Robert G. Maki | 100 | 416 | 39234 |
Louis R. Kavoussi | 95 | 544 | 31830 |
Howard Leventhal | 89 | 268 | 29144 |
Allan H. Young | 89 | 700 | 47369 |